Cincinnati Children's Hospital Medical Center Vaccine Research Center

Cincinnati, Ohio 45229-3039

1 studies enrolling now · 17 studies all time

What they study most

Avian Influenza, COVID -19, COVID-19, COVID-19 Immunisation, Campylobacter Infection, Ebola Disease, Escherichia Infection, Gastroenteritis Norovirus, Immunisation, Influenza, Influenza Immunisation, Monkeypox

Studies at this site

• Phase 2 Shigella Vaccine and Challenge — Completed
• A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine — Starting soon
• Safety and Immunogenicity of CJCV2 With and Without ALFQ — Completed
• Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children — Completed
• Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults — Running, not enrolling
• The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both Products — Completed
• Efficacy Study of IM Administered CssBA+dmLT Against Moderate-severe Diarrhea in Human Infection Model With ETEC Strain B7A in Healthy Adults — Completed
• A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age — Running, not enrolling
• A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox — Completed
• A Phase 1 Trial of Intranasal Mumps Virus Vaccines in Healthy Adults — Running, not enrolling
• Flublok or Fluzone With Advax-CpG55.2 or AF03 — Completed
• A Trial to Evaluate the Safety and Systems Biology Response of Ebolavirus Zaire Vaccine (ChAd3-EBO-Z) — Completed
• NNITS-Nitazoxanide for Norovirus in Transplant Patients Study — Completed
• Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines — Completed
• Phase I Norovirus Challenge Model — Completed
• H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults: Immunology — Completed
• Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in Naïve and Previously Vaccinated Adults — Completed